Free radicals are ubiquitous in our body and are generated by normal physiological processes, including aerobic metabolism and inflammatory responses, to eliminate invading pathogenic microorganisms. Chronic inflammation can increase cancer risk. We are investigating the interaction between nitric oxide (NO∙) and p53 as a crucial pathway in inflammatory-mediated carcinogenesis. We have shown previously that the p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress including nitric oxide, hydroxyl ions, hypoxia, and DNA replication arrest due to DNA damage by endogenous free radicals. Superoxide fluxes also limit nitric oxidend inactivates it by mutation of p53. Chronic inflammation activates the p53 tumor suppressor network and inactivates it by mutation of p53. Animal models are a critical facet of our integrative biology strategy, hence we have utilized genetic knockouts, e.g., p53 and inducible nitric oxide synthase, to investigate mechanisms of inflammation-associated cancer. Nitric oxide is involved in tumorigenesis. However, the quantity, redox-status, cell type and inflammatory microenvironment determine the pro- and anti-tumorigenic function of nitric oxide. Basal levels of nitric oxide delayed spontaneous tumor development in p53-deficient mice, when compared to mice lacking both p53 and nitric oxide synthase-2. This study provided genetic and mechanistic evidence that nitric oxide can suppress tumorigenesis. However, an inflammation-induced increase in the quantity of nitric oxide accelerated spontaneous tumor development in p53-deficient mice. An inflammatin-induced increase in nitric oxide production inhibited apoptosis and enhanced the production of immune suppressive regulatory T cells. These findings provide evidence that nitric oxide can be tumorigenic. Based on these observations, we propose a model of dose dependent modulation of tumorigenesis by nitric oxide under non-inflammatory and inflammatory microenvironment in a mouse model of cancer-prone Li-Fraumeni syndrome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010033-13
Application #
7732971
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2008
Total Cost
$735,101
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Stauffer, Jimmy K; Scarzello, Anthony J; Jiang, Qun et al. (2012) Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology 56:1567-74
Simone, Nicole L; Soule, Benjamin P; Ly, David et al. (2009) Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 4:e6377
Wink, David A; Ridnour, Lisa A; Hussain, S Perwez et al. (2008) The reemergence of nitric oxide and cancer. Nitric Oxide 19:65-7
Hussain, S Perwez; He, Peijun; Subleski, Jeffery et al. (2008) Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res 68:7130-6
Thomas, Douglas D; Ridnour, Lisa A; Isenberg, Jeffrey S et al. (2008) The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 45:18-31
Thomas, Douglas D; Ridnour, Lisa A; Espey, Michael Graham et al. (2006) Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem 281:25984-93
Goodman, Julie E; Mechanic, Leah E; Luke, Brian T et al. (2006) Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 118:1790-7
Ying, Lei; Marino, Jillian; Hussain, S Perwez et al. (2005) Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. Cancer Res 65:9132-6
Hofseth, Lorne J; Robles, Ana I; Espey, Michael G et al. (2005) Nitric oxide is a signaling molecule that regulates gene expression. Methods Enzymol 396:326-40
Hussain, S Perwez; Trivers, Glennwood E; Hofseth, Lorne J et al. (2004) Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 64:6849-53

Showing the most recent 10 out of 29 publications